MCID: NNT008
MIFTS: 38

Neonatal Abstinence Syndrome

Categories: Respiratory diseases, Mental diseases

Aliases & Classifications for Neonatal Abstinence Syndrome

Summaries for Neonatal Abstinence Syndrome

Disease Ontology : 12 A withdrawal disorder that is characterized by a group of problems that occur in a newborn who was exposed to addictive illegal or prescription drugs while in the mother's womb or postnatally following the discontinuance of drug treatment.

MalaCards based summary : Neonatal Abstinence Syndrome, also known as drug withdrawal syndrome in newborn, is related to drug dependence and chronic pain. An important gene associated with Neonatal Abstinence Syndrome is OPRM1 (Opioid Receptor Mu 1), and among its related pathways/superpathways are Interleukin-4 and 13 signaling and Imipramine/Desipramine Pathway, Pharmacokinetics. The drugs Clonidine and Opium have been mentioned in the context of this disorder. Affiliated tissues include brain and heart.

Related Diseases for Neonatal Abstinence Syndrome

Diseases related to Neonatal Abstinence Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 25)
# Related Disease Score Top Affiliating Genes
1 drug dependence 29.0 OPRD1 OPRK1 OPRM1
2 chronic pain 10.2 COMT OPRM1
3 heroin dependence 10.0 OPRD1 OPRM1
4 somatoform disorder 10.0 COMT OPRM1
5 aging 9.9
6 opioid abuse 9.9
7 sickle cell disease 9.9
8 specific developmental disorder 9.9 COMT OPRM1
9 phobic disorder 9.9 COMT OPRK1
10 pain agnosia 9.9 OPRK1 OPRM1
11 agnosia 9.8 OPRK1 OPRM1
12 tobacco addiction 9.8 COMT OPRM1
13 torticollis 9.8
14 stroke, ischemic 9.8
15 zika fever 9.8
16 cerebritis 9.8
17 zika virus infection 9.8
18 depression 9.8
19 disease of mental health 9.6 COMT OPRM1
20 morphine dependence 9.5 OPRD1 OPRK1 OPRM1
21 opiate dependence 9.4 OPRD1 OPRK1 OPRM1
22 cocaine dependence 9.4 OPRD1 OPRK1 OPRM1
23 substance dependence 9.4 OPRD1 OPRK1 OPRM1
24 alcohol dependence 8.9 COMT OPRD1 OPRK1 OPRM1
25 opioid addiction 7.9 COMT CYP2B6 OPRD1 OPRK1 OPRM1

Graphical network of the top 20 diseases related to Neonatal Abstinence Syndrome:



Diseases related to Neonatal Abstinence Syndrome

Symptoms & Phenotypes for Neonatal Abstinence Syndrome

Drugs & Therapeutics for Neonatal Abstinence Syndrome

Drugs for Neonatal Abstinence Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 67)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clonidine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4205-90-7 2803
2
Opium Approved, Illicit Phase 4 8008-60-4
3
Methadone Approved Phase 4,Phase 2,Phase 3,Not Applicable 76-99-3 4095
4
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 57-27-2 5288826
5
Phenobarbital Approved, Investigational Phase 4,Phase 3,Not Applicable 50-06-6 4763
6
Loperamide Approved Phase 4 53179-11-6 3955
7
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
8
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 93-14-1 3516
9
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
10 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2
11 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Narcotics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Analgesics, Opioid Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Opiate Alkaloids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Respiratory System Agents Phase 4,Phase 3,Phase 2,Not Applicable
18 Adrenergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
19 Adrenergic Agonists Phase 4,Phase 3,Phase 2,Not Applicable
20 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 3,Phase 2,Not Applicable
21 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 2,Not Applicable
22 Chlorpheniramine, phenylpropanolamine drug combination Phase 4,Phase 3,Phase 2,Not Applicable
23 GABA Agents Phase 4,Phase 3,Not Applicable
24 GABA Modulators Phase 4,Phase 3,Not Applicable
25 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2
26 Sympatholytics Phase 4,Phase 3,Phase 2,Not Applicable
27 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 3,Not Applicable
29 Hypnotics and Sedatives Phase 4,Phase 3,Not Applicable
30 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Not Applicable
31 Excitatory Amino Acid Antagonists Phase 4,Phase 3,Not Applicable
32 Excitatory Amino Acids Phase 4,Phase 3,Not Applicable
33 Anticonvulsants Phase 4,Phase 3,Not Applicable
34 Antidiarrheals Phase 4
35 Antitussive Agents Phase 4,Phase 3,Phase 2,Not Applicable
36 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Opium Poppy Nutraceutical Phase 4
38
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 52485-79-7 40400 644073
39
Chlorpromazine Approved, Investigational, Vet_approved Phase 3 50-53-3 2726
40
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
41
Cocaine Approved, Illicit Phase 2, Phase 3 50-36-2 5760 446220
42
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
43 Narcotic Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
44 Pharmaceutical Solutions Phase 3,Phase 1,Phase 2
45 Tranquilizing Agents Phase 3,Phase 1,Phase 2
46 Dopamine Agents Phase 3
47 Dopamine Antagonists Phase 3
48 Antiemetics Phase 3,Phase 1,Phase 2
49 Antipsychotic Agents Phase 3,Phase 1,Phase 2
50 Psychotropic Drugs Phase 3,Phase 1,Phase 2

Interventional clinical trials:

(show all 49)
# Name Status NCT ID Phase Drugs
1 Treatment of Neonatal Abstinence Syndrome Completed NCT01723722 Phase 4 Methadone;Diluted Deodorized Tincture of Opium
2 NAS Treatment - Opiate Versus Non-Opiate Completed NCT01734551 Phase 4 Morphine;Clonidine
3 Comparison Between Methadone and Morphine for Neonatal Opiate Withdrawal Completed NCT01804075 Phase 4 Methadone;Morphine
4 Treatment of Neonatal Abstinence Syndrome With Clonidine Versus Morphine as Primary Therapy Recruiting NCT03092011 Phase 4 Clonidine;Morphine Sulfate
5 Morphine Versus Methadone for Opiate Exposed Infants With Neonatal Abstinence Syndrome Recruiting NCT02851303 Phase 4 Morphine;Methadone
6 Blinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence Syndrome Completed NCT01452789 Phase 3 sublingual buprenorphine;oral morphine
7 Fetal and Infant Effects of Maternal Buprenorphine Treatment Completed NCT01561079 Phase 2, Phase 3 Buprenorphine
8 Maternal Acupuncture for Substance Abuse Completed NCT00225316 Phase 3
9 How to Treat Opiate Withdrawal in Neonates Completed NCT02810782 Phase 3 Phenobarbital;Chlorpromazine;Morphine
10 Tobacco Use in Opioid Agonist Treated Pregnant Women Completed NCT00497068 Phase 2, Phase 3
11 RCT Comparing Methadone and Buprenorphine in Pregnant Women Completed NCT00271219 Phase 3 Methadone;Buprenorphine
12 Recovery Housing For Drug Dependent Pregnant Women Completed NCT00497302 Phase 2, Phase 3
13 Non-Opiate Treatment After Prenatal Opiate Exposure to Prevent Postnatal Injury to the Young Brain Recruiting NCT03396588 Phase 3 Clonidine;Morphine
14 Improving Outcomes in Neonatal Abstinence Syndrome Active, not recruiting NCT01958476 Phase 3 Neonatal Morphine Solution;Methadone;Phenobarbital
15 The Effect of Aromatherapy on Neonatal Abstinence Syndrome and Salivary Cortisol Levels Enrolling by invitation NCT03097484 Phase 3 lavender and chamomile essential oils
16 Clonidine to Treat Iatrogenic-induced Opioid Dependence in Infants Terminated NCT01360450 Phase 2, Phase 3 Clonidine HCL;saline
17 Sublingual Buprenorphine Treatment for Neonatal Abstinence Syndrome - Pilot Study Unknown status NCT02249026 Phase 1, Phase 2 BZDs + opiate exposure treated with BPN;Opiates exposure treated with BPN
18 Clonidine as Adjunct Therapy for the Treatment of Neonatal Abstinence Syndrome Completed NCT00510016 Phase 2 Clonidine HCL
19 RCT of High- vs. Standard-Calorie Formula for Methadone-Exposed Infants Completed NCT02178189 Phase 2
20 How Pregnant Women and Their Babies Metabolize Ondansetron Compared to a Group of Non-pregnant Women Completed NCT01801475 Phase 1, Phase 2 Ondansetron
21 Can Ondansetron Prevent Neonatal Abstinence Syndrome (NAS) in Babies Born to Narcotic-dependent Women Recruiting NCT01965704 Phase 2 Ondansetron;Placebo
22 Methadone Demonstration Project Recruiting NCT03134703 Phase 2 Methadone;Morphine
23 Maternal Buprenorphine-naloxone Treatment and the Infant Recruiting NCT03291847 Phase 2 Buprenorphine Naloxone;Methadone
24 Comparison of Buprenorphine to Morphine in Treatment of Neonatal Abstinence Syndrome (NAS) Active, not recruiting NCT01708707 Phase 2 Buprenorphine;Morphine Sulfate
25 Efficacy of Auricular Acupuncture on Neonatal Abstinence Syndrome Not yet recruiting NCT02872077 Phase 1, Phase 2
26 Buprenorphine for Treatment of Neonatal Abstinence Syndrome in Infants With In Utero Exposure to Benzodiazepines Completed NCT01671410 Phase 1 oral morphine;sublingual buprenorphine
27 Buprenorphine for the Treatment of Neonatal Abstinence Syndrome Completed NCT00521248 Phase 1 buprenorphine;Oral morphine solution
28 Acupuncture in Neonatal Abstinence Syndrome (NAS) Babies Unknown status NCT02062151 Not Applicable
29 The Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome Completed NCT01754324 Methadone
30 Vagal Tone and Neonatal Abstinence Syndrome Completed NCT00496951
31 Weighted Blankets With Infants With NAS Completed NCT03113656 Not Applicable
32 Interest of Concentrations in Meconium of Buprenorphine and Methadone as a Prognostic Factor of NAS Outcome Completed NCT03334981
33 Buprenorphine Dose Adjustments and Gestational Age Completed NCT03028883
34 Utility of Psychosocial Intervention in Improving Outcome for Methadone-exposed Infants and Their Mothers Completed NCT01889121
35 The Effects of Methadone and Buprenorphine on Fetal Neurobehavior and Infant Neonatal Abstinence Syndrome - 1 Completed NCT00218621
36 RESPECT-PLUS: Services for Infants With Prenatal Opiate Exposure Completed NCT02334111 Not Applicable
37 Fetal Neurobehavior in Poly-drug Dependent Women Completed NCT00653692
38 Fetal Neurobehavioral Development in Methadone Maintained Pregnancies Completed NCT00067184
39 The Effect of Fetal Gender on Maternal Substance Abuse Treatment Completed NCT00882648
40 Conflict Between Maternal Autonomy and Child Health in Substance-use Completed NCT02797990
41 Effect of Music Therapy on Infants With Neonatal Abstinence Syndrome Recruiting NCT03533985 Not Applicable
42 Opioid Dependence Treatment Therapies in Pregnancy Recruiting NCT03098407 Not Applicable Buprenorphine;Methadone
43 Transmission of Chronic Hepatitis C in Pregnancy Recruiting NCT03570112 SOF/VEL- sofosbuvir 400mg and velpatasvir 100mg
44 Donor Human Milk in Neonatal Abstinence Syndrome Active, not recruiting NCT02182973
45 Role of Low Lactose Infant Formula In The Management of Neonatal Abstinence Syndrome Active, not recruiting NCT03549936 Not Applicable
46 Physiology and Therapeutic Management of Neonatal Abstinence Syndrome Enrolling by invitation NCT02768844
47 Efficacy and Outcomes of a Non-Pharmacological Intervention for Neonatal Abstinence Syndrome Enrolling by invitation NCT02801331 Not Applicable
48 Differences in Brain Activity Measures by Electroencephalogram (EEG) in Babies With Opioid Exposure Not yet recruiting NCT03567603
49 Clonidine for Neonatal Abstinence Syndrome Study Terminated NCT01175668 Not Applicable Clonidine;Phenobarbital

Search NIH Clinical Center for Neonatal Abstinence Syndrome

Cochrane evidence based reviews: neonatal abstinence syndrome

Genetic Tests for Neonatal Abstinence Syndrome

Anatomical Context for Neonatal Abstinence Syndrome

MalaCards organs/tissues related to Neonatal Abstinence Syndrome:

41
Brain, Heart

Publications for Neonatal Abstinence Syndrome

Articles related to Neonatal Abstinence Syndrome:

(show top 50) (show all 279)
# Title Authors Year
1
Comparison of outcomes between morphine and concomitant morphine and clonidine treatments for neonatal abstinence syndrome. ( 29972601 )
2018
2
Non-pharmacological interventions for neonatal abstinence syndrome. ( 29797741 )
2018
3
Mental Health of Mothers of Infants with Neonatal Abstinence Syndrome and Prenatal Opioid Exposure. ( 29417369 )
2018
4
Does Maternal Buprenorphine Dose Affect Severity or Incidence of Neonatal Abstinence Syndrome? ( 29905586 )
2018
5
Neonatal Abstinence Syndrome: Exploring Nurses' Attitudes, Knowledge, and Practice. ( 29360671 )
2018
6
Whole-family treatment of neonatal abstinence syndrome. ( 29661819 )
2018
7
Opioid Use in Pregnancy, Neonatal Abstinence Syndrome, and Childhood Outcomes: Executive Summary of a Joint Workshop by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, American College of Obstetricians and Gynecologists, American Academy of Pediatrics, Society for Maternal-Fetal Medicine, Centers for Disease Control and Prevention, and the March of Dimes Foundation. ( 29266062 )
2018
8
Changing Neonatal Nurses' Perceptions of Caring for Infants Experiencing Neonatal Abstinence Syndrome and Their Mothers: An Evidenced-Based Practice Opportunity. ( 29595550 )
2018
9
Neonatal abstinence syndrome: an update. ( 29346142 )
2018
10
Management of Neonatal Abstinence Syndrome: The Importance of a Multifaceted Program Spanning Inpatient and Outpatient Care. ( 29793879 )
2018
11
Torticollis in Infants with a History of Neonatal Abstinence Syndrome. ( 29395169 )
2018
12
Neonatal Abstinence Syndrome and the Pediatric Hospitalist: 5 Years Later. ( 29263123 )
2018
13
Safety of Reiki Therapy for Newborns at Risk for Neonatal Abstinence Syndrome. ( 29315084 )
2018
14
A Novel Approach to Assessing Infants With Neonatal Abstinence Syndrome. ( 29263121 )
2018
15
Maternal opioid use disorder and neonatal abstinence syndrome in northwest Ontario: a 7-year retrospective analysis. ( 29547380 )
2018
16
A Quality Improvement Initiative to Increase Scoring Consistency and Accuracy of the Finnegan Tool: Challenges in Obtaining Reliable Assessments of Drug Withdrawal in Neonatal Abstinence Syndrome. ( 29373349 )
2018
17
Treating Neonatal Abstinence Syndrome in a Rural Hospital: Lessons Learned. ( 29428413 )
2018
18
Quality improvement initiative to improve inpatient outcomes for Neonatal Abstinence Syndrome. ( 29740196 )
2018
19
The Epidemic of Neonatal Abstinence Syndrome, Historical References of Its' Origins, Assessment, and Management. ( 29520355 )
2018
20
Hospital Variation in Neonatal Abstinence Syndrome Incidence, Treatment Modalities, Resource Use, and Costs Across Pediatric Hospitals in the United States, 2013 to 2016. ( 29263122 )
2018
21
Finding the right treatment for neonatal abstinence syndrome: is this the right time? ( 29515226 )
2018
22
Association of Rooming-in With Outcomes for Neonatal Abstinence Syndrome: A Systematic Review and Meta-analysis. ( 29404599 )
2018
23
Neonatal Abstinence Syndrome: Advances in Diagnosis and Treatment. ( 29614184 )
2018
24
Neonatal Abstinence Syndrome (NAS) in Southwestern Border States: Examining Trends, Population Correlates, and Implications for Policy. ( 29572587 )
2018
25
Outpatient pharmacologic weaning for neonatal abstinence syndrome: a systematic review. ( 29739484 )
2018
26
Incidence and Costs of Neonatal Abstinence Syndrome Among Infants With Medicaid: 2004<b>-</b>2014. ( 29572288 )
2018
27
The effect of standardizing treatment when managing neonatal abstinence syndrome<sup/>. ( 29757685 )
2018
28
Comparison of Safety and Efficacy of Methadone vs Morphine for Treatment of Neonatal Abstinence Syndrome: A Randomized Clinical Trial. ( 29913015 )
2018
29
Opioid Utilization by Pregnant Women with Sickle Cell Disease and the Risk of Neonatal Abstinence Syndrome. ( 29580450 )
2018
30
Outpatient Pharmacotherapy for Neonatal Abstinence Syndrome. ( 29754866 )
2018
31
Social Ecological Examination of Factors That Influence the Treatment of Newborns With Neonatal Abstinence Syndrome. ( 29763579 )
2018
32
Nonpharmacological management of neonatal abstinence syndrome: a review of the literature. ( 29207895 )
2018
33
The Pharmacokinetics and Pharmacodynamics of Buprenorphine in Neonatal Abstinence Syndrome. ( 29516490 )
2018
34
Feeding Infants with Neonatal Abstinence Syndrome: Finding the Sweet Spot. ( 29436353 )
2018
35
The Role of Preterm Birth in the Association Between Opioid Maintenance Therapy and Neonatal Abstinence Syndrome. ( 29372750 )
2018
36
Pharmacists' and prescribers' neonatal abstinence syndrome (NAS) prevention behaviors: a preliminary analysis. ( 29209864 )
2017
37
Neonatal Abstinence Syndrome and Ethical Approaches to the Identification of Pregnant Women Who Use Drugs. ( 27926654 )
2017
38
A management strategy that reduces NICU admissions and decreases charges from the front line of the neonatal abstinence syndrome epidemic. ( 28682317 )
2017
39
Neonatal Abstinence Syndrome: Twins Case Series. ( 29312901 )
2017
40
Variations in Infant CYP2B6 Genotype Associated with the Need for Pharmacological Treatment for Neonatal Abstinence Syndrome in Infants of Methadone-Maintained Opioid-Dependent Mothers. ( 28320034 )
2017
41
Neonatal abstinence syndrome: Neurobehavior at 6 weeks of age in infants with or without pharmacological treatment for withdrawal. ( 28561904 )
2017
42
Neonatal abstinence syndrome and early childhood morbidity and mortality in Washington state: a retrospective cohort study. ( 28682319 )
2017
43
Buprenorphine for the Neonatal Abstinence Syndrome. ( 28877016 )
2017
44
Opioid Use and Abuse and Neonatal Abstinence Syndrome. ( 28726245 )
2017
45
An Initiative to Improve the Quality of Care of Infants With Neonatal Abstinence Syndrome. ( 28562267 )
2017
46
Neonatal Abstinence Syndrome Management: A Review of Recent Evidence. ( 28814260 )
2017
47
Buprenorphine for the Neonatal Abstinence Syndrome. ( 28877015 )
2017
48
The opioid epidemic and neonatal abstinence syndrome in the USA: a review of the continuum of care. ( 28073819 )
2017
49
Opioid Use in Pregnancy, Neonatal Abstinence Syndrome, and Childhood Outcomes: Executive Summary of a Joint Workshop by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, American College of Obstetricians and Gynecologists, American Academy of Pediatrics, Society for Maternal-Fetal Medicine, Centers for Disease Control and Prevention, and the March of Dimes Foundation. ( 28594753 )
2017
50
Association of maternal and infant variants in PNOC and COMT genes with neonatal abstinence syndrome severity. ( 27983768 )
2017

Variations for Neonatal Abstinence Syndrome

Expression for Neonatal Abstinence Syndrome

Search GEO for disease gene expression data for Neonatal Abstinence Syndrome.

Pathways for Neonatal Abstinence Syndrome

GO Terms for Neonatal Abstinence Syndrome

Cellular components related to Neonatal Abstinence Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dendrite GO:0030425 9.5 COMT OPRK1 OPRM1
2 neuron projection GO:0043005 9.43 OPRD1 OPRK1 OPRM1
3 perikaryon GO:0043204 9.37 OPRK1 OPRM1
4 axon terminus GO:0043679 9.16 OPRD1 OPRK1
5 dendrite membrane GO:0032590 8.96 OPRD1 OPRM1
6 intrinsic component of plasma membrane GO:0031226 8.62 LY96 OPRD1

Biological processes related to Neonatal Abstinence Syndrome according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.71 OPRD1 OPRK1 OPRM1
2 response to lipopolysaccharide GO:0032496 9.69 COMT LY96 OPRM1
3 neuropeptide signaling pathway GO:0007218 9.63 OPRD1 OPRK1 OPRM1
4 phospholipase C-activating G-protein coupled receptor signaling pathway GO:0007200 9.61 OPRD1 OPRK1 OPRM1
5 cellular response to lipopolysaccharide GO:0071222 9.59 LY96 OPRK1
6 response to ethanol GO:0045471 9.58 OPRK1 OPRM1
7 locomotory behavior GO:0007626 9.58 OPRK1 OPRM1
8 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.58 OPRD1 OPRK1 OPRM1
9 response to estrogen GO:0043627 9.57 COMT OPRK1
10 response to cocaine GO:0042220 9.56 OPRK1 OPRM1
11 response to radiation GO:0009314 9.55 OPRK1 OPRM1
12 adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway GO:0007193 9.54 OPRD1 OPRK1 OPRM1
13 response to morphine GO:0043278 9.52 OPRK1 OPRM1
14 sensory perception of pain GO:0019233 9.5 OPRD1 OPRK1 OPRM1
15 estrous cycle GO:0044849 9.49 OPRK1 OPRM1
16 sensory perception GO:0007600 9.48 OPRK1 OPRM1
17 eating behavior GO:0042755 9.33 OPRD1 OPRK1 OPRM1
18 adenylate cyclase-inhibiting opioid receptor signaling pathway GO:0031635 9.26 OPRK1 OPRM1
19 opioid receptor signaling pathway GO:0038003 9.13 OPRD1 OPRK1 OPRM1
20 regulation of sensory perception of pain GO:0051930 8.92 COMT OPRD1 OPRK1 OPRM1

Molecular functions related to Neonatal Abstinence Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide binding GO:0042277 9.33 OPRD1 OPRK1 OPRM1
2 neuropeptide binding GO:0042923 9.13 OPRD1 OPRK1 OPRM1
3 opioid receptor activity GO:0004985 8.8 OPRD1 OPRK1 OPRM1

Sources for Neonatal Abstinence Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....